- Home
- BUSE vs NAMS Comparison
BUSE vs NAMS Comparison
Compare BUSE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BUSE | NAMS |
|---|---|---|
| Founded | 1868 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 1996 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BUSE | NAMS |
|---|---|---|
| Price | $29.39 | $24.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $33.29 | ★ $50.65 |
| AVG Volume (30 Days) | 583.6K | ★ 1.7M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 32.81 |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $719,584,000.00 | $22,503,000.00 |
| Revenue This Year | $9.21 | $29.51 |
| Revenue Next Year | $2.07 | $383.46 |
| P/E Ratio | $24.51 | ★ N/A |
| Revenue Growth | ★ 55.66 | N/A |
| 52 Week Low | $22.00 | $21.02 |
| 52 Week High | $31.70 | $42.21 |
Technical Indicators
Market Signals| Indicator | BUSE | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 29.40 | 53.63 |
| Support Level | $28.29 | $21.02 |
| Resistance Level | $29.10 | $26.19 |
| Average True Range (ATR) | 0.50 | 1.23 |
| MACD | -0.14 | 0.45 |
| Stochastic Oscillator | 0.00 | 93.69 |
Price Performance
Historical ComparisonAbout BUSE First Busey Corporation
First Busey Corporation is a financial holding company whose subsidiaries provide retail and commercial banking services, remittance processing, and offer financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.